IL158155A0 - Use of erythropoietin to ameliorate chemotherapy-induced toxicity in vivo - Google Patents

Use of erythropoietin to ameliorate chemotherapy-induced toxicity in vivo

Info

Publication number: IL158155A0
Authority: IL; Israel
Prior art keywords: erythropoietin; vivo; induced toxicity; cytotoxic agent; ameliorate
Prior art date: 2001-04-09

Application number

IL15815502A

Other languages

English (en)

Original Assignee

Univ East Carolina

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-09

Filing date

2002-04-08

Publication date

2004-03-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23082337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL158155(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-08 Application filed by Univ East Carolina filed Critical Univ East Carolina

2004-03-28 Publication of IL158155A0 publication Critical patent/IL158155A0/xx

Links

102000003951 Erythropoietin Human genes 0.000 title abstract 4
108090000394 Erythropoietin Proteins 0.000 title abstract 4
229940105423 erythropoietin Drugs 0.000 title abstract 4
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 4
238000002512 chemotherapy Methods 0.000 title 1
238000001727 in vivo Methods 0.000 title 1
230000001988 toxicity Effects 0.000 title 1
231100000419 toxicity Toxicity 0.000 title 1
229940127089 cytotoxic agent Drugs 0.000 abstract 3
239000002254 cytotoxic agent Substances 0.000 abstract 3
231100000599 cytotoxic agent Toxicity 0.000 abstract 3
206010061924 Pulmonary toxicity Diseases 0.000 abstract 1
231100000374 pneumotoxicity Toxicity 0.000 abstract 1
230000007047 pulmonary toxicity Effects 0.000 abstract 1
230000007675 toxicity by organ Effects 0.000 abstract 1
231100000155 toxicity by organ Toxicity 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Zoology (AREA)
Toxicology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

IL15815502A 2001-04-09 2002-04-08 Use of erythropoietin to ameliorate chemotherapy-induced toxicity in vivo IL158155A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28262101P	2001-04-09	2001-04-09
PCT/US2002/011081 WO2002080676A1 (en)	2001-04-09	2002-04-08	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo

Publications (1)

Publication Number	Publication Date
IL158155A0 true IL158155A0 (en)	2004-03-28

Family

ID=23082337

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL15815502A IL158155A0 (en)	2001-04-09	2002-04-08	Use of erythropoietin to ameliorate chemotherapy-induced toxicity in vivo
IL158155A IL158155A (en)	2001-04-09	2003-09-29	Use of erythropoietin for the preparation of a medicament to ameliorate chemotherapy-induced toxicity
IL198783A IL198783A0 (en)	2001-04-09	2009-05-17	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
IL158155A IL158155A (en)	2001-04-09	2003-09-29	Use of erythropoietin for the preparation of a medicament to ameliorate chemotherapy-induced toxicity
IL198783A IL198783A0 (en)	2001-04-09	2009-05-17	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo

Country Status (22)

Country	Link
US (2)	US20020169128A1 (de)
EP (1)	EP1377164B1 (de)
JP (1)	JP4428924B2 (de)
KR (1)	KR100885525B1 (de)
CN (2)	CN101152565A (de)
AT (1)	ATE399020T1 (de)
AU (1)	AU2002256133B2 (de)
BR (1)	BR0208727A (de)
CA (1)	CA2443025A1 (de)
DE (1)	DE60227244D1 (de)
DK (1)	DK1377164T3 (de)
ES (1)	ES2309166T3 (de)
HU (1)	HUP0303838A3 (de)
IL (3)	IL158155A0 (de)
MX (1)	MXPA03009182A (de)
NO (1)	NO20034504L (de)
NZ (1)	NZ528675A (de)
PL (1)	PL373361A1 (de)
PT (1)	PT1377164E (de)
RU (1)	RU2296563C2 (de)
WO (1)	WO2002080676A1 (de)
ZA (1)	ZA200307803B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6926898B2 (en)	2000-04-12	2005-08-09	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
CA2841097A1 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin and g-csf fusion proteins
KR101163683B1 (ko)	2003-05-12	2012-07-10	아피맥스, 인크.	에리스로포이에틴 수용체에 결합하는 신규의 펩티드
CN1849141A (zh) *	2003-05-12	2006-10-18	阿费麦克斯公司	用于聚(乙二醇)修饰的肽的间隔臂部分
JP2007530440A (ja) *	2003-05-12	2007-11-01	アフィーマックス・インコーポレイテッド	新規ポリ（エチレングリコール）修飾化合物およびその用途
PL1625156T3 (pl) *	2003-05-12	2013-03-29	Affymax Inc	Peptydy wiążące się do receptora erytropoetyny
US20080312201A1 (en) *	2004-09-10	2008-12-18	Patrick Fogarty	Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
WO2006062685A2 (en) *	2004-11-11	2006-06-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
EP1814910A4 (de) *	2004-11-11	2009-04-29	Affymax Inc	Neue am erythropoietinrezeptor bindende peptide
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) *	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
EP2057997A4 (de) *	2006-08-22	2012-11-07	Chugai Pharmaceutical Co Ltd	Mittel zur prävention und/oder behandlung von peripherer neuropathie
WO2008050836A1 (en) *	2006-10-25	2008-05-02	Ajinomoto Co., Inc.	Agent for ameliorating adverse side-effect of chemotherapeutic agent
EP1992355A1 (de) *	2007-05-16	2008-11-19	Eberhardt Spanuth	Pharmazeutische Kombinationsmedikation mit NSAIDs oder zytoxischen Wirkstoffen
RU2410095C2 (ru) *	2009-04-20	2011-01-27	Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева"	Средство для повышения эффективности и снижения токсичности противоопухолевых препаратов
ES3063334T3 (en) *	2015-06-18	2026-04-16	Yeda Res & Dev	Conditioning protocols and use of same for tissue regeneration
US10695402B2 (en)	2017-03-16	2020-06-30	University Of Rochester	Erythropoietin for gastrointestinal dysfunction
WO2022159414A1 (en)	2021-01-22	2022-07-28	University Of Rochester	Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4859765A (en) *	1983-10-17	1989-08-22	Syntex (U.S.A.) Inc.	Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US4863857A (en) *	1985-03-01	1989-09-05	Board Of Regents, The University Of Texas System	Polypeptide complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known
NZ215865A (en) *	1985-04-22	1988-10-28	Commw Serum Lab Commission	Method of determining the active site of a receptor-binding analogue
IT210425Z2 (it) *	1987-01-22	1988-12-30	Erga Srl	Portachiavi con mezzo di scrittura telescopico incorporato
US4853871A (en) *	1987-04-06	1989-08-01	Genex Corporation	Computer-based method for designing stablized proteins
US4856871A (en) *	1987-08-31	1989-08-15	General Electric Company	Replaceable laser and lens assembly
JP2632014B2 (ja) *	1988-03-03	1997-07-16	中外製薬株式会社	骨髄機能障害性貧血治療剤
GB9613070D0 (en) *	1996-06-21	1996-08-28	Rowett Research Services Limit	Dietary lectins
US20020052309A1 (en) *	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury
US6719977B1 (en) *	1998-02-12	2004-04-13	The General Hospital Corporation	Methods to potentiate cancer therapies
WO2000067776A1 (en) *	1999-05-11	2000-11-16	Ortho-Mcneil Pharmaceuticals, Inc.	Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
US6531121B2 (en) *	2000-12-29	2003-03-11	The Kenneth S. Warren Institute, Inc.	Protection and enhancement of erythropoietin-responsive cells, tissues and organs

2002
- 2002-04-05 US US10/117,011 patent/US20020169128A1/en not_active Abandoned
- 2002-04-08 PL PL02373361A patent/PL373361A1/xx not_active Application Discontinuation
- 2002-04-08 RU RU2003132584/14A patent/RU2296563C2/ru not_active IP Right Cessation
- 2002-04-08 HU HU0303838A patent/HUP0303838A3/hu unknown
- 2002-04-08 PT PT02725577T patent/PT1377164E/pt unknown
- 2002-04-08 CN CNA2007101533855A patent/CN101152565A/zh active Pending
- 2002-04-08 MX MXPA03009182A patent/MXPA03009182A/es active IP Right Grant
- 2002-04-08 DE DE60227244T patent/DE60227244D1/de not_active Expired - Lifetime
- 2002-04-08 IL IL15815502A patent/IL158155A0/xx unknown
- 2002-04-08 KR KR1020037013132A patent/KR100885525B1/ko not_active Expired - Fee Related
- 2002-04-08 AT AT02725577T patent/ATE399020T1/de not_active IP Right Cessation
- 2002-04-08 AU AU2002256133A patent/AU2002256133B2/en not_active Ceased
- 2002-04-08 DK DK02725577T patent/DK1377164T3/da active
- 2002-04-08 WO PCT/US2002/011081 patent/WO2002080676A1/en not_active Ceased
- 2002-04-08 CA CA002443025A patent/CA2443025A1/en not_active Abandoned
- 2002-04-08 ES ES02725577T patent/ES2309166T3/es not_active Expired - Lifetime
- 2002-04-08 JP JP2002578724A patent/JP4428924B2/ja not_active Expired - Fee Related
- 2002-04-08 BR BR0208727-8A patent/BR0208727A/pt not_active IP Right Cessation
- 2002-04-08 NZ NZ528675A patent/NZ528675A/en unknown
- 2002-04-08 EP EP02725577A patent/EP1377164B1/de not_active Revoked
- 2002-04-08 CN CNB028078136A patent/CN100379446C/zh not_active Expired - Fee Related
2003
- 2003-09-29 IL IL158155A patent/IL158155A/en not_active IP Right Cessation
- 2003-10-06 ZA ZA200307803A patent/ZA200307803B/en unknown
- 2003-10-08 NO NO20034504A patent/NO20034504L/no not_active Application Discontinuation
2009
- 2009-05-17 IL IL198783A patent/IL198783A0/en unknown
2011
- 2011-03-31 US US13/077,335 patent/US20110195046A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE399020T1 (de)	2008-07-15
WO2002080676A1 (en)	2002-10-17
CN1499927A (zh)	2004-05-26
NO20034504L (no)	2003-12-09
MXPA03009182A (es)	2004-02-17
JP2004532840A (ja)	2004-10-28
RU2296563C2 (ru)	2007-04-10
KR100885525B1 (ko)	2009-02-26
ZA200307803B (en)	2005-02-09
US20020169128A1 (en)	2002-11-14
EP1377164A1 (de)	2004-01-07
DE60227244D1 (de)	2008-08-07
US20110195046A1 (en)	2011-08-11
CN100379446C (zh)	2008-04-09
NZ528675A (en)	2006-10-27
DK1377164T3 (da)	2008-10-13
KR20030087064A (ko)	2003-11-12
PL373361A1 (en)	2005-08-22
BR0208727A (pt)	2005-05-10
JP4428924B2 (ja)	2010-03-10
IL158155A (en)	2009-12-24
HUP0303838A2 (hu)	2004-03-01
NO20034504D0 (no)	2003-10-08
CA2443025A1 (en)	2002-10-17
ES2309166T3 (es)	2008-12-16
AU2002256133B2 (en)	2007-05-31
EP1377164A4 (de)	2005-05-04
RU2003132584A (ru)	2005-04-10
IL198783A0 (en)	2010-02-17
HUP0303838A3 (en)	2010-03-29
EP1377164B1 (de)	2008-06-25
CN101152565A (zh)	2008-04-02
PT1377164E (pt)	2008-09-30

Publication	Publication Date	Title
IL198783A0 (en)	2010-02-17	Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
AP2002002703A0 (en)	2002-12-31	Combinations of depeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diadetes mellitus.
YU71901A (sh)	2005-07-19	NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
SE0001899D0 (sv)	2000-05-22	New compounds
MY145590A (en)	2012-02-29	Phenylacetamides and their use as glucokinase modulators
MXPA04004842A (es)	2004-08-02	Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
EP1545483A4 (de)	2009-03-25	Nichtnukleosidische reverse-transkriptase-hemmer
MXPA05007470A (es)	2005-09-21	Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2.
DK1180121T3 (da)	2004-03-01	Langtidsvirkende insulinotrope peptider
MY121517A (en)	2006-01-28	Anticonvulsant derivatives useful in reducing blood glucose levels
WO2001092283A3 (en)	2002-07-04	Cobalamin compounds useful as cardiovascular agents and as imaging agents
DE60125417D1 (de)	2007-02-01	Verminderung der nebenwirkungen der chemotherapie in krebspatienten
PL1965797T3 (pl)	2011-07-29	Zmniejszenie zawrotów głowy, efektu ubocznego związanego z terapią pirfenidonem
GEP20043162B (en)	2004-01-26	Derivatives of Isosorbid Mononitrate, Utilization as Vasodilator Agents with Reduced Tolerance
MXPA02012730A (es)	2003-05-14	Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide.
ITMI20022394A1 (it)	2004-05-14	Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
EE05241B1 (et)	2009-12-15	Distamtsiini a-halogenoakrlolderivaadi kasutamine
MXPA01007210A (es)	2004-10-29	Agente para el tratamiento de enfermedad de parkinson que comprende un agente que mejora la funcion del astrocito como ingrediente activo.
EP1930023A3 (de)	2008-08-06	Erythropoietin reduziert die Chemotherapie-induzierte in vivo Toxizität
PL367630A1 (en)	2005-03-07	Use of acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
TW200500376A (en)	2005-01-01	Novel adenosine analogues and their use as pharmaceutical agents
WO2002051404A8 (fr)	2003-11-13	Compositions orales
MXPA04006269A (es)	2004-09-27	Composicion farmaceutica que comprende un inhibidor de alfa-glucosidasa y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.
AR030945A1 (es)	2003-09-03	Amidas de acido fenilciclohexanocarboxilico sustituido y su uso
WO2004091508A3 (en)	2007-01-11	Fullerene compositions for ameliorating dermatological conditions